InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plan

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease

Newron presents 2023 financial results and provides 2024 outlook

Biotalys and Novonesis announce manufacturing and commercialisation partnership for EVOCA NG

CRS initiates new chapter by appointing leading industry expert Elisabeth Lackner as Chief Executive Officer

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell